Tevogen Announces Reverse Stock Split

Core Viewpoint - Tevogen Bio Holdings Inc. has announced a reverse stock split at a ratio of 50 for 1 to comply with Nasdaq's minimum bid price requirement of $1.00, effective March 6, 2026 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 50 shares of common stock into one share, with no fractional shares issued; instead, cash will be provided for any fractional shares [3]. - The reverse stock split will not affect stockholders' percentage of ownership, except for changes due to fractional shares, and will not impact the company's business operations or total stockholders' equity [4]. Group 2: Company Overview - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing AI and precision T cell therapy platforms [8]. - The company has completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, with a pipeline that includes programs in virology, oncology, and neurology [9]. - Tevogen.AI aims to enhance drug development by improving target detection and clinical trial design through predictive technologies [10]. - Future strategic initiatives may include domestic generics, biosimilars, medical devices, and innovative insurance solutions [11].